Parkinson-kór: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

31+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · I01

  Peripheral orexin agonists to improve motor function in a mouse model of Parkinson’s Disease

  Minneapolis Va Medical Center· Minneapolis, Egyesült Államok· until 2030. szept.

• U.S. Department of Veterans Affairs · I01

  Clinical and Neuropathological Characterization of Parkinsonism Related to TBI in Veterans (CANPARK-TBI)

  James J Peters Va Medical Center· Bronx, Egyesült Államok· until 2030. szept.

• NIH NEI · R01

  Retinal Cell Loss in Diabetic Retinopathy

  Wayne State University· Detroit, Egyesült Államok· 387 500 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NIDDK · F31

  Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 435 842 EUR· until 2030. nov.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, Franciaország· EU contribution 226 421 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 2 113 066 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 1 500 000 EUR· until 2031. nov.

  The disease is named only in the funder's project summary, not in the title.

10 of 1408 running projects, newest first. Listed amounts together: 777,6 M USD + 184,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  High-Dose Ambroxol in GBA1-Related Parkinson

  NCT06193421· Agyany Pharma LTD· Frissítve: 2026. nov. 9.

  “Sponsor's decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

  NCT07011771· Capsida Biotherapeutics, Inc.· Frissítve: 2026. jún. 22.

  “Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Parkinson's Disease in Type 1 Gaucher Disease

  NCT07886879· Icahn School of Medicine at Mount Sinai· Forrás

• Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

  NCT06993142· Radboud University Medical Center· Forrás

• Ambroxol as a Disease-modifying Treatment in GBA-PD

  NCT05287503· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Forrás

• LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease

  NCT04668898· Icahn School of Medicine at Mount Sinai· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 25
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 186
• Genome-Wide Association Study 83

• Disease duration-dependent alteration of regulatory natural killer cells in patients with Parkinson's disease.

  Parkinsonism Relat Disord, 2026. ápr.

• Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species.

  Neurotoxicology, 2009. aug.

• Protective effects of hyperoside (quercetin-3-o-galactoside) to PC12 cells against cytotoxicity induced by hydrogen peroxide and tert-butyl hydroperoxide.

  Biomed Pharmacother, 2005. szept.

• Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway.

  Free Radic Biol Med, 2005. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.